Online first
Original article
Published online: 2024-08-08
Markers of the outcome of COVID-19
Abstract
Introduction: Over the last four years, COVID-19 has caused more than 3 million deaths around the world. This phenomenon led to the search for diagnostic markers for COVID-19. Considering that the clinical applicability of specific biomarkers for the prediction of the severity of COVID-19 is still debatable, this study analyses the clinical applicability of NT-proCNP, presepsin, SuPAR, Crp, procalcitonin, interleukin-6 and D-dimers in patients who died and survived COVID-19 to establish cross-relevance between the outcome of COVID-19 and markers level.
Materials and methods: The study sample comprised 84 deceased patients (62 men, 21 women) and 72 survivors (40 men, 32 women). Various immunological techniques were employed to analyse the concentration of specific biomarkers. Statistical analysis was performed using the Student’s t-test or the Mann-Whitney test according to the distribution of the sample studied.
Results: This study revealed that the levels of NT-proCNP, presepsin, SuPAR, procalcitonin, and IL-6 increase due to COVID-19. Thus, nonsurvivors are defined by the higher levels of those markers than the survivors.
Conclusions: The study revealed the potential application of NT-proCNP, presepsin, SuPAR, CRP, procalcitonin, IL-6, and D-dimers as markers of progression of the COVID-19 - D. However, considering the physiological mechanism of a dimension of a response of the studied markers as a function of disease progress, it may not be concluded that they are singularly unique for the progress of the COVID-19 - D.
Keywords: COVID-19markersoutcome
References
- World Health Organization, The true death toll of COVID-19: estimating global excess mortality. 2021. https://www.who.int/data/stories/the-true-death-toll-of-covid-19-estimating-global-excess-mortality.
- Galkin F, Parish A, Bischof E, et al. Increased Pace of Aging in COVID-Related Mortality. Life (Basel). 2021; 11(8).
- Cao X, Li W, Wang T, et al. Accelerated biological aging in COVID-19 patients. Nat Commun. 2022; 13(1): 2135.
- Reeves J, Kooner JS, Zhang W. Accelerated ageing is associated with increased COVID-19 severity and differences across ethnic groups may exist. Front Public Health. 2022; 10: 1034227.
- Valero-Bover D, Monterde D, Carot-Sans G, et al. Is Age the Most Important Risk Factor in COVID-19 Patients? The Relevance of Comorbidity Burden: A Retrospective Analysis of 10,551 Hospitalizations. Clin Epidemiol. 2023; 15: 811–825.
- Chan JFW, Yip CCY, To KKW, et al. Improved Molecular Diagnosis of COVID-19 by the Novel, Highly Sensitive and Specific COVID-19-RdRp/Hel Real-Time Reverse Transcription-PCR Assay Validated and with Clinical Specimens. J Clin Microbiol. 2020; 58(5).
- Letelier P, Encina N, Morales P, et al. Role of biochemical markers in the monitoring of COVID-19 patients. J Med Biochem. 2021; 40(2): 115–128.
- Kashyap A, Sebastian SA, Krishnaiyer NarayanaSwamy SR, et al. Molecular markers for early stratification of disease severity and progression in COVID-19. Biol Methods Protoc. 2022; 7(1): bpac028.
- Fialek B, Pruc M, Smereka J, et al. Diagnostic value of lactate dehydrogenase in COVID-19: A systematic review and meta-analysis. Cardiol J. 2022; 29(5): 751–758.
- Chi L, Wang S, Wang X, et al. Predictive value of C-reactive protein for disease severity and survival in COVID-19 patients: a systematic review and meta-analysis. Clin Exp Med. 2023; 23(6): 2001–2008.
- Kumar A, Karn E, Trivedi K, et al. Procalcitonin as a predictive marker in COVID-19: A systematic review and meta-analysis. PLoS One. 2022; 17(9): e0272840.
- Mardi A, Meidaninikjeh S, Nikfarjam S, et al. in COVID-19 Infection: Immunopathogenesis and Possible Therapeutic Perspective. Viral Immunol. 2021; 34(10): 679–688.
- Coomes EA, Haghbayan H. Interleukin-6 in Covid-19: A systematic review and meta-analysis. Rev Med Virol. 2020; 30(6): 1–9.
- Islam H, Chamberlain TC, Mui AL, et al. Elevated Interleukin-10 Levels in COVID-19: Potentiation of Pro-Inflammatory Responses or Impaired Anti-Inflammatory Action? Front Immunol. 2021; 12: 677008.
- Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clinical Chemistry and Laboratory Medicine (CCLM). 2020; 58(7): 1131–1134.
- Gong J, Dong H, Xia QS, et al. Correlation analysis between disease severity and inflammation-related parameters in patients with COVID-19: a retrospective study. BMC Infect Dis. 2020; 20(1): 963.
- Sohn KM, Lee SG, Kim HJi, et al. COVID-19 Patients Upregulate Toll-like Receptor 4-mediated Inflammatory Signaling That Mimics Bacterial Sepsis. J Korean Med Sci. 2020; 35(38): e343.
- Yudhawati R, Sakina S, Fitriah M. Interleukin-1β and Interleukin-10 Profiles and Ratio in Serum of COVID-19 Patients and Correlation with COVID-19 Severity: A Time Series Study. Int J Gen Med. 2022; 15: 8043–8054.
- Wang D, Hu Bo, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11): 1061–1069.
- Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395(10223): 507–513.
- Kyriazopoulou E, Leventogiannis K, Tavoulareas G, et al. Presepsin as a diagnostic and prognostic biomarker of severe bacterial infections and COVID-19. Sci Rep. 2023; 13(1): 3814.
- Matuszewski M, Ładny J, Rafique Z, et al. Prediction value of soluble urokinase plasminogen activator receptor (suPAR) in COVID-19 patients - a systematic review and meta-analysis. Ann Agric Environ Med. 2023; 30(1): 142–147.
- Naveed M, Naeem M, Ur Rahman M, et al. Review of potential risk groups for coronavirus disease 2019 (COVID-19). New Microbes New Infect. 2021; 41: 100849.
- Mufarrih SH, Qureshi NQ, Yunus R, et al. Influence of Increasing Age and Body Mass Index of Gender in COVID-19 Patients. J Womens Health (Larchmt). 2022; 31(6): 779–786.
- Nezhadmoghadam F, Tamez-Peña JG, Martinez-Ledesma E. Exploring the intersection of obesity and gender in COVID-19 outcomes in hospitalized Mexican patients: a comparative analysis of risk profiles using unsupervised machine learning. Front Public Health. 2024; 12: 1337432.
- Koziorowski D, Tomasiuk R, Szlufik S, et al. Inflammatory cytokines and NT-proCNP in Parkinson's disease patients. Cytokine. 2012; 60(3): 762–766.
- Tomasiuk R, Mikaszewska-Sokolewicz M, Szlufik S, et al. The prognostic value of concomitant assessment of NT-proCNP, C-reactive protein, procalcitonin and inflammatory cytokines in septic patients. Crit Care. 2014; 18(3): 440.
- Tomasiuk R. N-Terminal Pro-C-Type Natriuretic Peptide: The Novel Marker in Selected Disease Units. Protein Pept Lett. 2022; 29(2): 125–132.
- Caro-Codón J, Rey JR, Buño A, et al. CARD-COVID Investigators. Characterization of NT-proBNP in a large cohort of COVID-19 patients. Eur J Heart Fail. 2021; 23(3): 456–464.
- Bojti I, Przewosnik AS, Luxenburger H, et al. Decreased level of serum NT-proCNP associates with disease severity in COVID-19. Respir Res. 2023; 24(1): 174.
- Velissaris D, Zareifopoulos N, Karamouzos V, et al. Presepsin as a Diagnostic and Prognostic Biomarker in Sepsis. Cureus. 2021; 13(5): e15019.
- Enocsson H, Idoff C, Gustafsson A, et al. Soluble Urokinase Plasminogen Activator Receptor (suPAR) Independently Predicts Severity and Length of Hospitalisation in Patients With COVID-19. Front Med (Lausanne). 2021; 8: 791716.
- Matuszewski M, Ładny J, Rafique Z, et al. Prediction value of soluble urokinase plasminogen activator receptor (suPAR) in COVID-19 patients - a systematic review and meta-analysis. Ann Agric Environ Med. 2023; 30(1): 142–147.
- Ali N. Elevated level of C-reactive protein may be an early marker to predict risk for severity of COVID-19. J Med Virol. 2020; 92(11): 2409–2411.
- Bouayed MZ, Laaribi I, Chatar CE, et al. C-Reactive Protein (CRP): A poor prognostic biomarker in COVID-19. Front Immunol. 2022; 13: 1040024.
- Tong-Minh K, van der Does Y, Engelen S, et al. High procalcitonin levels associated with increased intensive care unit admission and mortality in patients with a COVID-19 infection in the emergency department. BMC Infect Dis. 2022; 22(1): 165.
- Hu R, Han C, Pei S, et al. Procalcitonin levels in COVID-19 patients. Int J Antimicrob Agents. 2020; 56(2): 106051.
- Ahmed S, Jafri L, Hoodbhoy Z, et al. Prognostic Value of Serum Procalcitonin in COVID-19 Patients: A Systematic Review. Indian J Crit Care Med. 2021; 25(1): 77–84.
- Narazaki M, Kishimoto T. The Two-Faced Cytokine IL-6 in Host Defense and Diseases. Int J Mol Sci. 2018; 19(11).
- Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014; 6(10): a016295.
- Talwar D, Kumar S, Acharya S, et al. Interleukin 6 and Its Correlation with COVID-19 in Terms of Outcomes in an Intensive Care Unit of a Rural Hospital:A Cross-sectional Study. Indian J Crit Care Med. 2022; 26(1): 39–42.
- Sakka M, Connors JM, Hékimian G, et al. Association between D-Dimer levels and mortality in patients with coronavirus disease 2019 (COVID-19): a systematic review and pooled analysis. J Med Vasc. 2020; 45(5): 268–274.
- Tomasiuk R, Dabrowski J, Smykiewicz J, et al. Predictors of COVID-19 Hospital Treatment Outcome. Int J Gen Med. 2021; 14: 10247–10256.